Multi-omic landscape of human gliomas from diagnosis to treatment and recurrence

Hadeesha Piyadasa¹, Benjamin Oberlton², Mikaela Ribi³, Ke Leow⁴, Jolene S Ranek¹, Inna Averbukh¹, Meelad Amouzgar², Candace C Liu², Davide G Franchina¹, Noah F Greenwald⁴, Erin F McCaffrey¹, Rashmi Kumar¹, Selena Ferrian¹, Albert G Tsai¹, Ferda Filiz¹, Christine Camacho Fullaway¹, Marc Bosse¹, Sricharan Reddy Varra¹, Alex Kong¹, Cameron Sowers¹, Melanie Hayden Gephart⁵, Pablo Nuñez-Perez⁵, EnJun Yang⁶, Mike Travers⁶, Michael J Schachter⁶, Samantha Liang⁶, Maria R Santi⁷, Samantha Bucktrout⁶, Pier Federico Gherardini⁸, John Connolly⁶, Kristina Cole⁷, Michael E Barish⁹, Christine E Brown¹⁰, Derek A Oldridge¹¹, Richard R Drake¹², Joanna J Phillips¹³, Hideho Okada¹⁴, Robert Prins¹⁵, Sean C Bendall¹⁶, Michael Angelo¹⁷

Affiliations

¹ Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
² Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA; Immunology Program, Stanford University School of Medicine, Stanford, CA, USA.
³ Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA; Department of Chemistry and Sarafan ChEM-H, Stanford University, Stanford, CA, USA.
⁴ Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA; Cancer Biology Program, Stanford University School of Medicine, Stanford, CA, USA.
⁵ Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA, USA.
⁶ Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
⁷ Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
⁸ Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA; Department of Biology, University of Rome "Tor Vergata", Rome, Italy.
⁹ Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA; Department of Stem Cell Biology and Regenerative Medicine, Beckman Research Institute of the City of Hope, Duarte, CA, USA.
¹⁰ Departments of Hematology & Hematopoietic Cell Transplantation and Immuno-Oncology, Beckman Research Institute of the City of Hope, Duarte, CA, USA.
¹¹ Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA; Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA; Center for Computational and Genomic Medicine, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
¹² Department of Pharmacology and Immunology, Medical University of South Carolina, Charleston, SC, USA.
¹³ Department of Pathology, University of California, San Francisco, San Francisco, CA, USA; Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA.
¹⁴ Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA; Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA.
¹⁵ Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA; Department of Neurosurgery, UCLA, Los Angeles, CA, USA.
¹⁶ Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA; Immunology Program, Stanford University School of Medicine, Stanford, CA, USA; Cancer Biology Program, Stanford University School of Medicine, Stanford, CA, USA; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA. Electronic address: bendall@stanford.edu.
¹⁷ Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA; Immunology Program, Stanford University School of Medicine, Stanford, CA, USA; Cancer Biology Program, Stanford University School of Medicine, Stanford, CA, USA; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA. Electronic address: mangelo0@stanford.edu.

PMID: 41386224
DOI: 10.1016/j.ccell.2025.11.006

Multi-omic landscape of human gliomas from diagnosis to treatment and recurrence

Hadeesha Piyadasa et al. Cancer Cell. 2026.

. 2026 Jan 12;44(1):112-128.e6.

doi: 10.1016/j.ccell.2025.11.006. Epub 2025 Dec 11.

Authors

Affiliations

¹ Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA.
² Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA; Immunology Program, Stanford University School of Medicine, Stanford, CA, USA.
³ Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA; Department of Chemistry and Sarafan ChEM-H, Stanford University, Stanford, CA, USA.
⁴ Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA; Cancer Biology Program, Stanford University School of Medicine, Stanford, CA, USA.
⁵ Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA, USA.
⁶ Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
⁷ Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
⁸ Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA; Department of Biology, University of Rome "Tor Vergata", Rome, Italy.
⁹ Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA; Department of Stem Cell Biology and Regenerative Medicine, Beckman Research Institute of the City of Hope, Duarte, CA, USA.
¹⁰ Departments of Hematology & Hematopoietic Cell Transplantation and Immuno-Oncology, Beckman Research Institute of the City of Hope, Duarte, CA, USA.
¹¹ Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA; Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA; Center for Computational and Genomic Medicine, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
¹² Department of Pharmacology and Immunology, Medical University of South Carolina, Charleston, SC, USA.
¹³ Department of Pathology, University of California, San Francisco, San Francisco, CA, USA; Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA.
¹⁴ Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA; Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA.
¹⁵ Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA; Department of Neurosurgery, UCLA, Los Angeles, CA, USA.
¹⁶ Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA; Immunology Program, Stanford University School of Medicine, Stanford, CA, USA; Cancer Biology Program, Stanford University School of Medicine, Stanford, CA, USA; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA. Electronic address: bendall@stanford.edu.
¹⁷ Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA; Immunology Program, Stanford University School of Medicine, Stanford, CA, USA; Cancer Biology Program, Stanford University School of Medicine, Stanford, CA, USA; Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA. Electronic address: mangelo0@stanford.edu.

PMID: 41386224
DOI: 10.1016/j.ccell.2025.11.006

Abstract

Gliomas are among the most lethal cancers, with limited treatment options. To uncover hallmarks of therapeutic escape and tumor microenvironment (TME) landscape, we applied spatial proteomics, transcriptomics, and glycomics to 670 lesions from 310 adult and pediatric patients. Single-cell analysis shows high B7H3+ tumor cell prevalence in glioblastoma (GBM) and pleomorphic xanthoastrocytoma, while most gliomas, including pediatric cases, express targetable tumor antigens in less than 50% of tumor cells, potentially explaining trial failures. Paired samples of isocitrate dehydrogenase (IDH)-mutant gliomas reveal recurrence driven by tumor-immune spatial reorganization, shifting from T cell and vasculature-associated myeloid cell-enriched niches to microglia and CD206⁺ macrophage-dominated tumors. Multi-omic integration identified N-glycosylation as the best classifier of grade, while the immune transcriptome best predicted GBM survival. Provided as a community resource, this study offers a framework for glioma targeting, classification, outcome prediction, and a baseline of TME composition across all stages.

Keywords: GBM; TME; diffuse midline glioma; glioma; immune regulation; immunotherapy; single-cell profiling; spatial N-glycome; spatial multi-omics; tumor antigens.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests M. Angelo and S.B. are named inventors on patent US20150287578A1, which covers the mass spectrometry approach utilized by MIBI-TOF. M. Angelo and S.B. are board members and shareholders in IonPath, which develops and manufactures the commercial MIBI-TOF platform.

Update of

Multi-omic landscape of human gliomas from diagnosis to treatment and recurrence.
Piyadasa H, Oberlton B, Ribi M, Ranek JS, Averbukh I, Leow K, Amouzgar M, Liu CC, Greenwald NF, McCaffrey EF, Kumar R, Ferrian S, Tsai AG, Filiz F, Fullaway CC, Bosse M, Varra SR, Kong A, Sowers C, Gephart MH, Nuñez-Perez P, Yang E, Travers M, Schachter MJ, Liang S, Santi MR, Bucktrout S, Gherardini PF, Connolly J, Cole K, Barish ME, Brown CE, Oldridge DA, Drake RR, Phillips JJ, Okada H, Prins R, Bendall SC, Angelo M. Piyadasa H, et al. bioRxiv [Preprint]. 2025 Apr 9:2025.03.12.642624. doi: 10.1101/2025.03.12.642624. bioRxiv. 2025. Update in: Cancer Cell. 2026 Jan 12;44(1):112-128.e6. doi: 10.1016/j.ccell.2025.11.006. PMID: 40161803 Free PMC article. Updated. Preprint.

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

Grants and funding

R35 NS105068/NS/NINDS NIH HHS/United States

LinkOut - more resources

Full Text Sources
- Elsevier Science
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Multi-omic landscape of human gliomas from diagnosis to treatment and recurrence

Affiliations

Multi-omic landscape of human gliomas from diagnosis to treatment and recurrence

Authors

Affiliations

Abstract

Conflict of interest statement

Update of

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Research Materials